A group of U.S. senators is examining Marathon Pharmaceuticals LLC’s decision to charge $89,000 in the U.S. for an old steroidal drug that costs a fraction of that overseas, the latest sign of growing scrutiny of the company.
from WSJ.com: US Business http://ift.tt/2ltWIsE
via IFTTT
No comments:
Post a Comment